MERIT-HF

Metoprolol CR/XL Randomized Intervention Trial in Heart Failure

Paciente / Población Intervención / Exposición Comparación Desenlace

In 3,991 patients with HFrEF (EF ≤ 0.40, NYHA II–IV), metoprolol CR/XL reduced all-cause mortality compared with placebo.

3991

Diseño

Double-blind RCT, terminated early

Desenlace

All-cause mortality

Relevancia

Resultado7.2 % vs 11.0 % per patient-year (34 % RRR).

MERIT-HF Study Group. Lancet. 1999;353(9169):2001-2007. 10.1016/S0140-6736(99)04440-2

Discusión y crítica

Established β-blockade as a pillar. Together with CIBIS-II (bisoprolol) and COPERNICUS (carvedilol), defined the prognostic β-blockers in HF.